NCT06857747 2025-03-04
Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Unknown
Clinical Trials
91 trialsNCT04922658 2024-07-31
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Unknown
NCT04400695 2024-01-24
A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
RemeGen Co., Ltd.
Phase 3 Unknown
NCT06211881 2024-01-18
Chi-GVM Regimen for the Treatment of R/R PTCL
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT02465736 2024-01-16
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)
Sun Yat-sen University
Phase 3 Unknown
NCT03620032 2023-12-06
DIPG
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT05296577 2023-09-25
Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT05823623 2023-09-14
Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04262804 2023-08-22
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
Zai Lab (Hong Kong), Ltd.
Phase 2 Unknown
NCT04304352 2023-06-28
VEX
European Institute of Oncology
Phase 2 Unknown
NCT05764941 2023-03-27
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Unknown
NCT00431704 2023-03-24
VinCaT
National Cancer Institute, Naples
Phase 2 Unknown
NCT05747326 2023-02-28
Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05603013 2022-11-02
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04848454 2022-10-18
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy
Peking University First Hospital
Phase 2 Unknown
NCT04605575 2022-04-26
Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT02607215 2022-04-20
Platinum Rechallenge in Patients With Platinum-sensitive mTNBC
Fudan University
Phase 2 Unknown
NCT04745975 2022-04-20
Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer
Fudan University
Phase 2 Unknown
NCT04389073 2022-02-25
Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05131841 2021-11-23
Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC
Zhejiang Cancer Hospital
Phase 4 Unknown
NCT02448797 2021-07-20
EVIDENCE
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
NCT04963595 2021-07-15
Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT04681911 2020-12-23
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT04665986 2020-12-14
Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer
Zhejiang Cancer Hospital
Phase 3 Unknown
NCT02977169 2020-11-13
To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Shanghai Chest Hospital
Phase 2 Unknown
NCT03402048 2020-11-04
EPIC
University of Turin, Italy
Phase 3 Unknown
NCT03270007 2020-10-28
Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy
Peking University
Phase 4 Unknown
NCT03939871 2020-06-23
A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT04115410 2020-05-28
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Unknown
NCT02733380 2020-04-01
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Unknown
NCT04307147 2020-03-13
NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy
Fudan University
Phase 3 Unknown
NCT04302441 2020-03-10
A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy
Fudan University
Phase 2 Unknown
NCT04208854 2019-12-26
VINORELBINA
International Group of Endovascular Oncology
Unknown
NCT03656094 2019-12-09
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors
Samsung Medical Center
Phase 2 Unknown
NCT04143906 2019-10-30
Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT04021992 2019-08-06
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL
Sun Yat-sen University
Phase 2 Unknown
NCT03997539 2019-06-25
A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT02768415 2019-06-19
Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT03933982 2019-05-29
Pyrotinib
ChineseAMS
Phase 2 Unknown
NCT03947242 2019-05-15
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.
Henan Cancer Hospital
Phase NA Unknown
NCT03932526 2019-04-30
Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT03925233 2019-04-24
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
Unknown
NCT03703427 2018-10-12
Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT03656393 2018-09-04
RCTACSCNSCLC
Shenzhen People's Hospital
Phase 3 Unknown
NCT03188159 2018-03-29
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
National University Hospital, Singapore
Phase 2 Unknown
NCT03423849 2018-02-06
The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy
Shandong Cancer Hospital and Institute
Phase 2/3 Unknown
NCT03359694 2017-12-02
Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT02489409 2017-07-17
Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer
Xinjiang Medical University
Phase 2 Unknown
NCT02144194 2017-02-09
TNM
Cancer Research Group - Collaborative Group, Beirut, Lebanon.
Phase 2 Unknown
NCT03006614 2017-01-16
PERS
Sun Yat-sen University
Phase 3 Unknown